{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:42:44Z","timestamp":1773272564444,"version":"3.50.1"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T00:00:00Z","timestamp":1651276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"Netherlands Organisation for Health Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004243","name":"Prinses Beatrix Spierfonds","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009480","name":"Friends of the Sophia Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009480","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods &amp; Clinical Development"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.omtm.2022.04.016","type":"journal-article","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T12:17:40Z","timestamp":1651666660000},"page":"520-532","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Lentiviral gene therapy prevents anti-human acid \u03b1-glucosidase antibody formation in murine Pompe disease"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1397-0714","authenticated-orcid":false,"given":"Qiushi","family":"Liang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva C.","family":"Vlaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Catalano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joon M.","family":"Pijnenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6030-1820","authenticated-orcid":false,"given":"Merel","family":"Stok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvette","family":"van Helsdingen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnold G.","family":"Vulto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9484-261X","authenticated-orcid":false,"given":"Wendy W.J.","family":"Unger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ans T.","family":"van der Ploeg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7042-2482","authenticated-orcid":false,"given":"W.W.M. Pim","family":"Pijnappel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niek P.","family":"van Til","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2022.04.016_bib1","series-title":"The Metabolic and Molecular Basis for Inherited Disease","first-page":"3389","article-title":"Glycogen storage disease type II: acid \u03b1-glucosidase (acid maltase) deficiency","author":"Hirschhorn","year":"2001"},{"key":"10.1016\/j.omtm.2022.04.016_bib2","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe's disease","volume":"372","author":"van der Ploeg","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2022.04.016_bib3","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1542\/peds.112.2.332","article-title":"The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature","volume":"112","author":"van den Hout","year":"2003","journal-title":"Pediatrics"},{"key":"10.1016\/j.omtm.2022.04.016_bib4","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J.\u00a0Pediatr."},{"key":"10.1016\/j.omtm.2022.04.016_bib5","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/ana.410380316","article-title":"Genotype-phenotype correlation in adult-onset acid maltase deficiency","volume":"38","author":"Wokke","year":"1995","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtm.2022.04.016_bib6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ajmg.c.31318","article-title":"The genotype-phenotype correlation in Pompe disease","volume":"160C","author":"Kroos","year":"2012","journal-title":"Am. J. Med. Genet. C Semin. Med. Genet."},{"key":"10.1016\/j.omtm.2022.04.016_bib7","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/brain\/awh384","article-title":"Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients","volume":"128","author":"Hagemans","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.omtm.2022.04.016_bib8","first-page":"875","article-title":"The natural course of non-classic Pompe's disease; a review of 225 published cases","volume":"252","author":"Winkel","year":"2005","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.omtm.2022.04.016_bib9","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1093\/hmg\/8.12.2145","article-title":"Human acid alpha-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II","volume":"8","author":"Bijvoet","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2022.04.016_bib10","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/j.1432-1033.1995.903_a.x","article-title":"Isolation and characterisation of a recombinant, precursor form of lysosomal acid alpha-glucosidase","volume":"234","author":"Fuller","year":"1995","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.omtm.2022.04.016_bib11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1073\/pnas.93.1.65","article-title":"High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease","volume":"93","author":"Van Hove","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U\u00a0S\u00a0A"},{"key":"10.1016\/j.omtm.2022.04.016_bib12","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1542\/peds.113.5.e448","article-title":"Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk","volume":"113","author":"Van den Hout","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.omtm.2022.04.016_bib13","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.nmd.2004.10.009","article-title":"Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial","volume":"15","author":"Klinge","year":"2005","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtm.2022.04.016_bib14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jpeds.2006.02.035","article-title":"Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease","volume":"149","author":"Kishnani","year":"2006","journal-title":"J.\u00a0Pediatr."},{"key":"10.1016\/j.omtm.2022.04.016_bib15","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/ana.20019","article-title":"Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up","volume":"55","author":"Winkel","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtm.2022.04.016_bib16","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/GIM.0b013e31819d0996","article-title":"Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease","volume":"11","author":"Nicolino","year":"2009","journal-title":"Genet. Med."},{"key":"10.1016\/j.omtm.2022.04.016_bib17","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.nmd.2010.07.277","article-title":"Effect of enzyme therapy in juvenile patients with Pompe disease: a three-year open-label study","volume":"20","author":"van Capelle","year":"2010","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtm.2022.04.016_bib18","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1750-1172-8-49","article-title":"Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study","volume":"8","author":"Gungor","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.omtm.2022.04.016_bib19","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1023\/A:1010383421286","article-title":"Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk","volume":"24","author":"Van den Hout","year":"2001","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.omtm.2022.04.016_bib20","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1203\/PDR.0b013e3181b24e94","article-title":"Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease","volume":"66","author":"Kishnani","year":"2009","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.omtm.2022.04.016_bib21","first-page":"91","article-title":"Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial","volume":"257","author":"Strothotte","year":"2010","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.omtm.2022.04.016_bib22","first-page":"952","article-title":"Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years","volume":"259","author":"Angelini","year":"2012","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.omtm.2022.04.016_bib23","doi-asserted-by":"crossref","first-page":"e1756","DOI":"10.1212\/WNL.0000000000008441","article-title":"Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease","volume":"93","author":"Harlaar","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.omtm.2022.04.016_bib24","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1212\/WNL.0000000000004711","article-title":"Long-term benefit of enzyme replacement therapy in Pompe disease: a 5-year prospective study","volume":"89","author":"Kuperus","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.omtm.2022.04.016_bib25","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s10545-010-9206-3","article-title":"Treatment of infantile Pompe disease with alglucosidase alpha: the UK experience","volume":"33","author":"Chakrapani","year":"2010","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.omtm.2022.04.016_bib26","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ymgme.2016.01.013","article-title":"Observational clinical study of 22 adult-onset Pompe disease patients undergoing enzyme replacement therapy over 5years","volume":"117","author":"Stepien","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.omtm.2022.04.016_bib27","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.omtm.2022.04.016_bib28","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s10545-014-9728-1","article-title":"Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS-LSD cohort study","volume":"37","author":"Anderson","year":"2014","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.omtm.2022.04.016_bib29","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","article-title":"A randomized study of alglucosidase alfa in late-onset Pompe's disease","volume":"362","author":"van der Ploeg","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2022.04.016_bib30","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/dmcn.13740","article-title":"Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain","volume":"60","author":"Ebbink","year":"2018","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.omtm.2022.04.016_bib31","doi-asserted-by":"crossref","first-page":"9419","DOI":"10.1073\/pnas.0902534106","article-title":"Neural deficits contribute to respiratory insufficiency in Pompe disease","volume":"106","author":"DeRuisseau","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U\u00a0S\u00a0A"},{"key":"10.1016\/j.omtm.2022.04.016_bib32","first-page":"45","article-title":"Postmortem findings and clinical correlates in individuals with infantile-onset pompe disease","volume":"23","author":"Pena","year":"2015","journal-title":"JIMD Rep."},{"key":"10.1016\/j.omtm.2022.04.016_bib33","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.molmed.2003.08.004","article-title":"Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder","volume":"9","author":"Brooks","year":"2003","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.omtm.2022.04.016_bib34","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/nbt.1484","article-title":"Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment","volume":"26","author":"Wang","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtm.2022.04.016_bib35","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","article-title":"The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease","volume":"13","author":"Banugaria","year":"2011","journal-title":"Genet. Med."},{"key":"10.1016\/j.omtm.2022.04.016_bib36","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10545-014-9707-6","article-title":"Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease","volume":"38","author":"van Gelder","year":"2015","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.omtm.2022.04.016_bib37","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.omtm.2022.04.016_bib38","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/gim.2015.6","article-title":"CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy","volume":"17","author":"Berrier","year":"2015","journal-title":"Genet. Med."},{"key":"10.1016\/j.omtm.2022.04.016_bib39","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/gim.2016.70","article-title":"Pompe disease in adulthood: effects of antibody formation on enzyme replacement therapy","volume":"19","author":"de Vries","year":"2017","journal-title":"Genet. Med."},{"key":"10.1016\/j.omtm.2022.04.016_bib40","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ymgme.2010.08.009","article-title":"High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa","volume":"101","author":"de Vries","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.omtm.2022.04.016_bib41","first-page":"100475","article-title":"Characterization of immune response in Cross-Reactive Immunological Material (CRIM)-positive infantile Pompe disease patients treated with enzyme replacement therapy","volume":"20","author":"Desai","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.omtm.2022.04.016_bib42","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1056\/NEJMc0806809","article-title":"Elimination of antibodies to recombinant enzyme in Pompe's disease","volume":"360","author":"Mendelsohn","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2022.04.016_bib43","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/gim.2011.4","article-title":"Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease","volume":"14","author":"Messinger","year":"2012","journal-title":"Genet. Med."},{"key":"10.1016\/j.omtm.2022.04.016_bib44","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jpeds.2017.11.046","article-title":"High sustained antibody titers in patients with classic infantile pompe disease following immunomodulation at start of enzyme replacement therapy","volume":"195","author":"Poelman","year":"2018","journal-title":"J.\u00a0Pediatr."},{"key":"10.1016\/j.omtm.2022.04.016_bib45","doi-asserted-by":"crossref","first-page":"e67052","DOI":"10.1371\/journal.pone.0067052","article-title":"Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT","volume":"8","author":"Banugaria","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.omtm.2022.04.016_bib46","first-page":"30","article-title":"Immune tolerance strategies in siblings with infantile pompe disease-advantages for a preemptive approach to high-sustained antibody titers","volume":"4","author":"Stenger","year":"2015","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.omtm.2022.04.016_bib47","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jpeds.2013.03.002","article-title":"B-Cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease","volume":"163","author":"Elder","year":"2013","journal-title":"J.\u00a0Pediatr."},{"key":"10.1016\/j.omtm.2022.04.016_bib48","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13023-019-1039-z","article-title":"Effects of immunomodulation in classic infantile Pompe patients with high antibody titers","volume":"14","author":"Poelman","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.omtm.2022.04.016_bib49","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/jimd.12268","article-title":"Effects of higher and more frequent dosing of alglucosidase alfa and immunomodulation on long-term clinical outcome of classic infantile Pompe patients","volume":"43","author":"Poelman","year":"2020","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.omtm.2022.04.016_bib50","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1016\/S2352-3026(19)30021-3","article-title":"Lentiviral haemopoietic stem\/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1\/2 clinical study","volume":"6","author":"Ferrua","year":"2019","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.omtm.2022.04.016_bib51","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1056\/NEJMoa1705342","article-title":"Gene therapy in\u00a0patients with transfusion-dependent beta-thalassemia","volume":"378","author":"Thompson","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2022.04.016_bib52","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1056\/NEJMoa1700554","article-title":"Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy","volume":"377","author":"Eichler","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2022.04.016_bib53","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(16)30374-9","article-title":"Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1\/2 trial","volume":"388","author":"Sessa","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2022.04.016_bib54","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T\u00a0cell proliferation in two patients after gene therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.omtm.2022.04.016_bib55","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omtm.2022.04.016_bib56","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/hmg\/7.1.53","article-title":"Generalized glycogen storage and cardiomegaly in a knockout mouse model of Pompe disease","volume":"7","author":"Bijvoet","year":"1998","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2022.04.016_bib57","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/(SICI)1096-9896(199911)189:3<416::AID-PATH445>3.0.CO;2-6","article-title":"Pathological features of glycogen storage disease type II highlighted in the knockout mouse model","volume":"189","author":"Bijvoet","year":"1999","journal-title":"J.\u00a0Pathol."},{"key":"10.1016\/j.omtm.2022.04.016_bib58","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1152\/physiolgenomics.2001.5.4.171","article-title":"Cardiac remodeling and contractile function in acid alpha-glucosidase knockout mice","volume":"5","author":"Kamphoven","year":"2001","journal-title":"Physiol. Genomics"},{"key":"10.1016\/j.omtm.2022.04.016_bib59","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.1182\/blood-2009-11-252874","article-title":"Lentiviral gene therapy of murine hematopoietic stem cells ameliorates the Pompe disease phenotype","volume":"115","author":"van Til","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2022.04.016_bib60","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.omtm.2020.04.023","article-title":"Lentiviral hematopoietic stem cell gene therapy corrects murine pompe disease","volume":"17","author":"Stok","year":"2020","journal-title":"Mol. Ther. - Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2022.04.016_bib61","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ymgme.2003.08.022","article-title":"Enzyme replacement therapy in the mouse model of Pompe disease","volume":"80","author":"Raben","year":"2003","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.omtm.2022.04.016_bib62","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/jgm.1305","article-title":"Partial phenotypic correction and immune tolerance induction to enzyme replacement therapy after hematopoietic stem cell gene transfer of alpha-glucosidase in Pompe disease","volume":"11","author":"Douillard-Guilloux","year":"2009","journal-title":"J.\u00a0Gene Med."},{"key":"10.1016\/j.omtm.2022.04.016_bib63","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1086\/522236","article-title":"Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance","volume":"81","author":"Sun","year":"2007","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.omtm.2022.04.016_bib64","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1097\/00007890-198706000-00008","article-title":"Bone marrow transplantation with T-cell-depleted grafts. II. Reconstitution of immunohemopoietic functions in lethally irradiated mice transplanted with unseparated or T-cell-depleted bone marrow grafts disparate at minor histocompatibility antigens","volume":"43","author":"Leshem","year":"1987","journal-title":"Transplantation"},{"key":"10.1016\/j.omtm.2022.04.016_bib65","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/jcmm.12227","article-title":"The peripheral chimerism of bone marrow-derived stem cells after transplantation: regeneration of gastrointestinal tissues in lethally irradiated mice","volume":"18","author":"Filip","year":"2014","journal-title":"J.\u00a0Cell Mol. Med."},{"key":"10.1016\/j.omtm.2022.04.016_bib66","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10545-015-9912-y","article-title":"Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study","volume":"39","author":"van Gelder","year":"2016","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.omtm.2022.04.016_bib67","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/jgm.1511","article-title":"Antibody formation and mannose-6-phosphate receptor expression impact the efficacy of muscle-specific transgene expression in murine Pompe disease","volume":"12","author":"Sun","year":"2010","journal-title":"J.\u00a0Gene Med."},{"key":"10.1016\/j.omtm.2022.04.016_bib68","first-page":"2686","article-title":"Immune response hinders therapy for lysosomal storage diseases","volume":"118","author":"Ponder","year":"2008","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omtm.2022.04.016_bib69","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2174\/156652309790031094","article-title":"Immunomodulatory gene therapy in lysosomal storage disorders","volume":"9","author":"Koeberl","year":"2009","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.omtm.2022.04.016_bib70","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.3324\/haematol.2011.058644","article-title":"Hematopoietic stem cell transplantation improves the high incidence of neutralizing allo-antibodies observed in Hurler's syndrome after pharmacological enzyme replacement therapy","volume":"97","author":"Saif","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.omtm.2022.04.016_bib71","doi-asserted-by":"crossref","first-page":"36182","DOI":"10.1038\/srep36182","article-title":"Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients","volume":"6","author":"Masat","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtm.2022.04.016_bib72","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ymgme.2016.01.011","article-title":"Enzyme replacement therapy prior to haematopoietic stem cell transplantation in Mucopolysaccharidosis Type I: 10 year combined experience of 2 centres","volume":"117","author":"Ghosh","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.omtm.2022.04.016_bib73","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1126\/science.2125367","article-title":"Induction by antigen of intrathymic apoptosis of CD4+CD8+TCRlo thymocytes in\u00a0vivo","volume":"250","author":"Murphy","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.omtm.2022.04.016_bib74","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1073\/pnas.93.7.3031","article-title":"Intravenous injection of soluble antigen induces thymic and peripheral T-cells apoptosis","volume":"93","author":"Liblau","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U\u00a0S\u00a0A"},{"key":"10.1016\/j.omtm.2022.04.016_bib75","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1111\/jth.13800","article-title":"Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T\u00a0cell mediated","volume":"15","author":"Chen","year":"2017","journal-title":"J.\u00a0Thromb. Haemost."},{"key":"10.1016\/j.omtm.2022.04.016_bib76","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.ymthe.2019.04.014","article-title":"Targeting a pre-existing anti-transgene T\u00a0cell response for effective gene therapy of MPS-I in the mouse model of the disease","volume":"27","author":"Squeri","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2022.04.016_bib77","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3390\/cells10051077","article-title":"Combining mobilizing agents with busulfan to reduce chemotherapy-based conditioning for hematopoietic stem cell transplantation","volume":"10","author":"Garcia-Perez","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.omtm.2022.04.016_bib78","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.ymthe.2019.05.022","article-title":"Busulfan combined with immunosuppression allows efficient engraftment of gene-modified cells in a rhesus macaque model","volume":"27","author":"Uchida","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2022.04.016_bib79","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/mt.2009.312","article-title":"Intensive pharmacological immunosuppression allows for repetitive liver gene transfer with recombinant adenovirus in nonhuman primates","volume":"18","author":"Fontanellas","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2022.04.016_bib80","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1038\/s41409-021-01378-8","article-title":"EBMT\/ESID inborn errors working party guidelines for hematopoietic stem cell transplantation for inborn errors of immunity","volume":"56","author":"Lankester","year":"2021","journal-title":"Bone Marrow Transpl."},{"key":"10.1016\/j.omtm.2022.04.016_bib81","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1515\/jpem-2018-0336","article-title":"Early higher dosage of alglucosidase alpha in classic Pompe disease","volume":"31","author":"Spada","year":"2018","journal-title":"J.\u00a0Pediatr. Endocrinol. Metab."},{"key":"10.1016\/j.omtm.2022.04.016_bib82","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13023-018-0771-0","article-title":"Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy","volume":"13","author":"Parini","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.omtm.2022.04.016_bib83","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0092-8674(94)90331-X","article-title":"Negative selection of lymphocytes","volume":"76","author":"Nossal","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.omtm.2022.04.016_bib84","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1182\/blood.V99.12.4394","article-title":"Induction of T-cell tolerance to an MHC class I alloantigen by gene therapy","volume":"99","author":"Bagley","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2022.04.016_bib85","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.4049\/jimmunol.169.4.1930","article-title":"Induction of central deletional T\u00a0cell tolerance by gene therapy","volume":"169","author":"Kang","year":"2002","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omtm.2022.04.016_bib86","doi-asserted-by":"crossref","first-page":"6768","DOI":"10.1182\/blood-2011-02-334623","article-title":"Thymic T-cell development in allogeneic stem cell transplantation","volume":"117","author":"Krenger","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2022.04.016_bib87","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.4049\/jimmunol.176.6.3410","article-title":"Induction of alloreactive CD4 T\u00a0cell tolerance in molecular chimeras: a possible role for regulatory T\u00a0cells","volume":"176","author":"Forman","year":"2006","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omtm.2022.04.016_bib88","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1089\/hum.2011.063","article-title":"Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease","volume":"23","author":"Zhang","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2022.04.016_bib89","doi-asserted-by":"crossref","first-page":"103737","DOI":"10.1016\/j.cellimm.2017.12.011","article-title":"Immunomodulatory, liver depot gene therapy for Pompe disease","volume":"342","author":"Bond","year":"2019","journal-title":"Cell Immunol."},{"key":"10.1016\/j.omtm.2022.04.016_bib90","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.omtm.2016.12.010","article-title":"Low-dose liver-targeted gene therapy for pompe disease enhances therapeutic efficacy of ERT via immune tolerance induction","volume":"4","author":"Han","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2022.04.016_bib91","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10545-015-9898-5","article-title":"Response of 33\u00a0UK patients with infantile-onset Pompe disease to enzyme replacement therapy","volume":"39","author":"Broomfield","year":"2016","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.omtm.2022.04.016_bib92","doi-asserted-by":"crossref","first-page":"e86821","DOI":"10.1172\/jci.insight.86821","article-title":"Durable and sustained immune tolerance to ERT in Pompe disease with entrenched immune responses","volume":"1","author":"Kazi","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.omtm.2022.04.016_bib93","doi-asserted-by":"crossref","first-page":"9873","DOI":"10.1128\/JVI.72.12.9873-9880.1998","article-title":"Self-inactivating lentivirus vector for safe and efficient in\u00a0vivo gene delivery","volume":"72","author":"Zufferey","year":"1998","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2022.04.016_bib94","doi-asserted-by":"crossref","first-page":"11382","DOI":"10.1073\/pnas.93.21.11382","article-title":"Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector","volume":"93","author":"Naldini","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U\u00a0S\u00a0A"},{"key":"10.1016\/j.omtm.2022.04.016_bib95","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.1128\/JVI.72.11.8463-8471.1998","article-title":"A third-generation lentivirus vector with a conditional packaging system","volume":"72","author":"Dull","year":"1998","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2022.04.016_bib96","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ymgme.2005.10.016","article-title":"A new diagnostic assay for glycogen storage disease type II in mixed leukocytes","volume":"88","author":"Okumiya","year":"2006","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.omtm.2022.04.016_bib97","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.omtn.2017.03.002","article-title":"GAA deficiency in pompe disease is alleviated by exon inclusion in iPSC-derived skeletal muscle cells","volume":"7","author":"van der Wal","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"}],"container-title":["Molecular Therapy - Methods &amp; Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S232905012200064X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S232905012200064X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:32:37Z","timestamp":1762421557000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S232905012200064X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":97,"alternative-id":["S232905012200064X"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2022.04.016","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lentiviral gene therapy prevents anti-human acid \u03b1-glucosidase antibody formation in murine Pompe disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2022.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s).","name":"copyright","label":"Copyright"}]}}